Toll-like receptor 1

Function

The binding of ligands to TLR1 activates intracellular signaling cascades leading to an inflammatory response and initiation of immune processes.

TLR1 cooperates with TLR2 in the recognition of bacterial triacyl lipoproteins. TLR1 has been shown to recognize the outer surface lipoprotein of Borrelia burgdorferi. The important role of TLR1 in recognizing triacyl lipopeptides has been shown in TLR1-deficient mice.

Toll-like receptors, including TLR-1, found on the epithelial cell layer that lines the small and large intestine are important players in the management of the gut microbiota and detection of pathogens.

Expression

TLR1 is synthesized in the endoplasmic reticulum. The trafficking of TLR1 from endoplasmic reticulum is controlled by protein associated with TLR4 (PRAT4A), which is endoplasmic reticulum resident chaperone. TLR1 is then transported to Golgi complex and to cell membrane.

TLR1 mRNA was expressed at high levels in the kidney, lung, and spleen in adult humans, but in low levels in fetal brain and liver as well as in HeLa cell line.

TLR1 is expressed in the highest levels on NK cells compared to other TLRs. TLR1 has been found to be expressed on human peripheral blood γδT cells, myeloid-derived suppressor cells, platelets, CD4+ T cells, microglia, astrocytes, immature dendritic cells, LTi-like innate lymphoid cells and eosinophils. It is also found on the surface of macrophages and neutrophils.

Structure

TLR1 is a type I transmembrane glycoprotein composed of extracellular, transmembrane and intracellular domains.

The extracellular domain of TLR1 contains leucine-rich repeat (LRR) domains, which play a crucial role in binding PAMPs. The LRR domains can be further categorized into three subdomains: the N-terminal, central, and C-terminal regions. While the N-terminal and C-terminal domains of TLR1 exhibit relative consistency with a consensus amino acid structure represented as xLxxLxxLxLxxNxLxxLPxxxFx, the central domains display significant variability. Notably, the central domains of TLR1 lack the presence of stabilizing asparagine ladders, which contribute to the typical horseshoe-like shape of the extracellular domain of TLRs. Furthermore, the number of residues within the LRR domains of the central region varies between 20 and 33 residues. Additionally, extra alpha helices were found in central domains of TLR1. The biological function of TLR1 is closely linked to the structural modifications in its extracellular domain, which are responsible for its capacity to bind ligands.

The intracellular domain of TLR1 consists of a toll/interleukin-1 receptor (TIR) domain, which is shared by various adaptor proteins involved in the signaling cascade initiated by TLRs. The TIR domain of TLR1 has been found as a monomer in the crystal structure.

TLR1 is able to recognize ligands as a complex with TLR2, referred to as TLR2/1 heterodimer. TLR2 can heterodimerize also with TLR6 forming TLR2/6 heterodimer. TLR2/1 adopts an "m"-shaped conformation when interacted with its ligands. The "m" shape conformation is formed by extracellular domains of TLR1 and TLR2, bringing the transmembrane and intracellular domains in close association. This conformational arrangement subsequently triggers a downstream signaling cascade.

TLR2/1 specifically recognizes triacyl lipopeptides, whereas TLR2/6 recognizes diacyl lipopeptides. Diacyl and triacyl lipopeptides are present on the bacterial outer membrane. In the case of triacyl lipopeptides, the mechanism behind their recognition lies in the incorporation of two lipid chains into the hydrophobic pocket of TLR2, while the remaining lipid chain inserts into a hydrophobic pocket of TLR1. Regarding TLR6, the hydrophobic pocket is obstructed by the side chains of two phenylalanine residues, resulting in a smaller pocket than in TLR1. This structural difference accounts for the distinct ligand specificities exhibited by TLR2/1 and TLR2/6 heterodimers.

Interactions

TLR1 has been shown to interact with TLR2. TLR1 recognizes peptidoglycan and (triacyl) lipopeptides in concert with TLR2 (as a heterodimer).

References

References

1. (January 1998). "A family of human receptors structurally related to Drosophila Toll". Proceedings of the National Academy of Sciences of the United States of America.
2. (January 2002). "Toll-like receptors". Critical Care Medicine.
3. "UniProt".
4. (2003). "Toll-like receptors". Annual Review of Immunology.
5. (April 2015). "Toll-like receptors". Current Protocols in Immunology.
6. (2014). "Regulation of Intestinal Immune Responses through TLR Activation: Implications for Pro- and Prebiotics". Frontiers in Immunology.
7. (June 2018). "Toll-like receptors in immunity and inflammatory diseases: Past, present, and future". International Immunopharmacology.
8. (May 2005). "Tissue-specific mRNA expression profiles of human toll-like receptors and related genes". Biological & Pharmaceutical Bulletin.
9. (May 2012). "Pattern-recognition receptors in human eosinophils". Immunology.
10. (August 2008). "Structures of the toll-like receptor family and its ligand complexes". Immunity.
11. (April 2011). "The structural biology of Toll-like receptors". Structure.
12. (January 2021). "TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects". Journal of Medicinal Chemistry.
13. (July 2002). "Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins". Journal of Immunology.
14. (March 2008). "Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling". Journal of Leukocyte Biology.
15. (September 2007). "Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide". Cell.